MX2019010913A - Analogos de deutetrabenazina, su preparacion y uso. - Google Patents

Analogos de deutetrabenazina, su preparacion y uso.

Info

Publication number
MX2019010913A
MX2019010913A MX2019010913A MX2019010913A MX2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A
Authority
MX
Mexico
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
MX2019010913A
Other languages
English (en)
Spanish (es)
Inventor
Kerr Jim
Zhang Chengzi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2019010913A publication Critical patent/MX2019010913A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Machine Translation (AREA)
  • Pens And Brushes (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
MX2019010913A 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso. MX2019010913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
MX2019010913A true MX2019010913A (es) 2020-01-20

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010913A MX2019010913A (es) 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso.

Country Status (20)

Country Link
US (4) US11813232B2 (enExample)
EP (1) EP3596077A1 (enExample)
JP (3) JP7608050B2 (enExample)
KR (2) KR20200003791A (enExample)
CN (1) CN110709398A (enExample)
AR (1) AR111182A1 (enExample)
AU (2) AU2018236336B2 (enExample)
BR (1) BR112019018966A2 (enExample)
CA (1) CA3056612A1 (enExample)
CL (1) CL2019002629A1 (enExample)
CO (1) CO2019011271A2 (enExample)
EA (1) EA201992168A1 (enExample)
IL (1) IL269132A (enExample)
MX (1) MX2019010913A (enExample)
PE (1) PE20191819A1 (enExample)
SG (1) SG11201908477QA (enExample)
TW (1) TWI772382B (enExample)
UA (1) UA127052C2 (enExample)
WO (1) WO2018170214A1 (enExample)
ZA (1) ZA201906326B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
WO2020123900A1 (en) 2018-12-13 2020-06-18 Auspex Pharmaceuticals, Inc. Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
EP4153136B1 (en) * 2020-06-10 2024-01-10 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
CA2736409C (en) * 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CN114767672A (zh) 2015-03-06 2022-07-22 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
US11813232B2 (en) 2017-03-15 2023-11-14 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use

Also Published As

Publication number Publication date
AU2018236336B2 (en) 2022-02-24
NZ757789A (en) 2024-08-30
US11179386B2 (en) 2021-11-23
AR111182A1 (es) 2019-06-12
KR20200003791A (ko) 2020-01-10
CA3056612A1 (en) 2018-09-20
US11813232B2 (en) 2023-11-14
EA201992168A1 (ru) 2020-03-16
AU2022203369B2 (en) 2024-04-04
US20180263972A1 (en) 2018-09-20
EP3596077A1 (en) 2020-01-22
CN110709398A (zh) 2020-01-17
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
KR20230003308A (ko) 2023-01-05
TWI772382B (zh) 2022-08-01
US12502385B2 (en) 2025-12-23
PE20191819A1 (es) 2019-12-27
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21
CO2019011271A2 (es) 2020-02-28
AU2022203369A1 (en) 2022-06-09
US20220040170A1 (en) 2022-02-10
JP2024050724A (ja) 2024-04-10
US20220088006A1 (en) 2022-03-24
UA127052C2 (uk) 2023-03-29
US20200016148A1 (en) 2020-01-16
TW201840317A (zh) 2018-11-16
JP2020510073A (ja) 2020-04-02
JP7631572B2 (ja) 2025-02-18
JP7608050B2 (ja) 2025-01-06
JP2023010754A (ja) 2023-01-20
IL269132A (en) 2019-11-28
BR112019018966A2 (pt) 2020-04-22
WO2018170214A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2023008686A (es) Polinucleotidos moduladores.
TWD180147S (zh) 淨水器
MX385845B (es) Usos y composiciones de la flagelina
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12017500836A1 (en) Transdermal formulations
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
MX2015016603A (es) Composiciones de corticosteroides.
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
MX363625B (es) Composiciones dentifricas con estabilidad mejorada del fluoruro.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
EA201890209A1 (ru) Композиция, содержащая танины
MX2016011416A (es) Composiciones de glicoproteinas sialiladas y usos de estas.
NZ721832A (en) Solid forms of tenofovir
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.